Key points are not available for this paper at this time.
In patients with operable gastric or lower esophageal adenocarcinomas, a perioperative regimen of ECF decreased tumor size and stage and significantly improved progression-free and overall survival. (Current Controlled Trials number, ISRCTN93793971 controlled-trials.com.).
Cunningham et al. (Thu,) studied this question.